A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes
| 대상 질환 | Preeclampsia Postpartum, Adverse Pregnancy Outcomes |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | University of Alabama at Birmingham |
| 상태 | 완료 |
| 참여자 수 | 61 명 |
| 중재(약물) | usual postpartum care, usual postpartum care + community health worker intervention |
| 시작일 | 2024년 9월 3일 |
| 완료일 | 2025년 6월 2일 |
| 결과 공개일 | 2026년 8월 5일 |
요약
United States maternal mortality and preterm birth rates are among the highest among high-income countries due in part to a combination of racial, regional and socioeconomic disparities in access to care and overall health. The research proposed focuses on adapting and expanding a perinatal community health worker intervention for Black postpartum patients with preeclampsia (PE) and other adverse pregnancy outcomes (APOs). Investigators will partner with a community-based organization that trains and deploys community health workers. Investigators will test an intervention for urban and rural Black postpartum patients with APOs to 1) enhance blood pressure control postpartum and 2) promote long-term cardiovascular disease prevention for this underserved population. This pilot study will determine if randomizing and implementing a community health worker intervention tailored to pregnant people experiencing preeclampsia is feasible and found to be acceptable by participants.
Participant Satisfaction With Postpartum Support
| Usual Care and Community Health Worker Intervention | 10 units on a scale |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Improving Hypertension Medication Adherence for Older Adults — University of Arizona
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
- SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca
- Utility of At-home Monitoring of Exercise Capacity by App-based 6-minute Walk Test — Stanford University